The rising incidence of cancer worldwide has led to an increasing number of surgeries that involve the removal of lymph nodes. Although these procedures play a major role in cancer staging and preventing the spread of malignancies, they sometimes come with severe long-term consequences. Since lymph nodes do not naturally regenerate once removed, their absence can lead to a condition known as secondary lymphedema. It manifests as chronic swelling, discomfort, and reduced mobility in affected limbs or regions, severely affecting a patient’s quality of life.
Consequently, a major focus within the field of regenerative medicine is the development of strategies to restore or regenerate damaged lymphatic structures to effectively treat secondary lymphedema. Existing approaches have largely centered on stem cells and lymphatic tissue transplantation. However, these techniques often require complex preparation protocols and, more importantly, have demonstrated limited efficacy in improving the key clinical symptoms of lymphedema.
Against this backdrop, a research team led by Associate Professor Kosuke Kusamori from the Faculty of Pharmaceutical Sciences at Tokyo University of Science (TUS), Japan, is pioneering an innovative technique for lymphatic tissue engineering that could revolutionize the treatment of secondary lymphedema. Their study, published in Volume 16 of the journal Nature Communications on November 19, 2025, describes a straightforward protocol to produce bioengineered lymphatic tissues that can restore lymphatic flow after the removal of lymph nodes. This work was co-authored by second-year doctoral student Mr. Shu Obana, Assistant Professor Shoko Itakura, and Professor Makiya Nishikawa, also from TUS.
The proposed approach is based on a novel centrifugal cell stacking technique to bioengineer replacement tissue for surgically removed lymph nodes. First, the researchers placed mesenchymal stem cells (MSCs), which are known to support tissue regeneration and provide structural scaffolding, in the wells of a Transwell culture plate. By centrifuging the entire plate, MSCs settled down uniformly at the bottom of the wells, forming a first layer. Then, the researchers added lymphatic endothelial cells to the wells, followed by another round of centrifugation to spread them evenly as a second layer. Finally, following a final centrifugation step after adding MSCs again, the result was a three-layered cellular structure, which the researchers called centrifuge-based bioengineered lymphatic tissue (CeLyT).
Using a lymphedema animal model, the team regenerated functional lymph node that exhibited structural similarity with native lymph node. They confirmed that transplanting CeLyTs restored lymphatic flow in mice whose popliteal and inguinal lymph nodes in the right lower limb had been removed. As a result, these mice exhibited remarkable improvement in lymphedema symptoms, with the thickness of their paws and legs returning to normal within a few weeks. Additionally, mice that received CeLyTs also showed recovery of filtration capacity and immune cell populations such as T cells and macrophages, and lower accumulation of adipose tissue in affected areas, reaching levels similar to normal mice.
The researchers carefully analyzed the structures that formed after CeLyT transplantation to shed light on the observed therapeutic effects. “CeLyTs may initially induce lymph and blood vessel formation around the transplantation site, leading to the establishment of an immature lymph node-like structure formed by incorporating host-derived cells into the tissue within several days, followed by its maturation and ability to function as a lymph node within 10 days after transplantation,” explains Dr. Kusamori.
This study marks the world’s first successful regeneration of fully functional lymph nodes through cell transplantation, offering a promising therapeutic option for patients who develop lymphedema, following oncologic surgeries involving lymph node dissection. Economically, a single transplantation could provide long-lasting therapeutic benefits, substantially reducing the cumulative costs associated with repeated hospital visits and long-term use of compression garments. Overall, these results highlight the strong curative potential of introducing appropriately bioengineered tissue into the lymphatic system, surpassing the efficacy of current treatment options for lymphedema.
“Although compression therapy represents the gold standard for the treatment of lymphedema in clinical practice, it usually delays the swelling in the paws of lymphedema mice. By contrast, CeLyTs were more effective at suppressing lymphedema, also exhibiting strong therapeutic effects even in a more severe chronic lymphedema model,” remarks Dr. Kusamori. “Moreover, CeLyTs demonstrated a greater lymphedema-suppressive effect, compared with bioengineered tissues fabricated by other tissue engineering methods.”
Let’s hope for CeLyTs to be translated into clinical practice!
***
Reference
DOI: 10.1038/s41467-025-65121-3
About The Tokyo University of Science
Tokyo University of Science (TUS) is a well-known and respected university, and the largest science-specialized private research university in Japan, with four campuses in central Tokyo and its suburbs and in Hokkaido. Established in 1881, the university has continually contributed to Japan's development in science through inculcating the love for science in researchers, technicians, and educators.
With a mission of “Creating science and technology for the harmonious development of nature, human beings, and society," TUS has undertaken a wide range of research from basic to applied science. TUS has embraced a multidisciplinary approach to research and undertaken intensive study in some of today's most vital fields. TUS is a meritocracy where the best in science is recognized and nurtured. It is the only private university in Japan that has produced a Nobel Prize winner and the only private university in Asia to produce Nobel Prize winners within the natural sciences field.
Website: https://www.tus.ac.jp/en/mediarelations/
About Associate Professor Kosuke Kusamori from Tokyo University of Science
Dr. Kosuke Kusamori obtained a PhD in Pharmaceutical Sciences from Kyoto University in 2013. He joined Tokyo University of Science in 2017, where he currently serves as an Associate Professor. His primary research interest is in biopharmaceutics, biomedical and biomaterials engineering, cell-based therapies, and regenerative medicine. He has published over 90 peer-reviewed research papers. He is affiliated with academic societies such as The Academy of Pharmaceutical Science and Technology, Japan.
Funding information
This work was supported by a Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science (grant number 23H03749), Project Seeds A from the Japan Agency for Medical Research and Development (grant number A409TS) JST SPRING (grant number JPMJSP2151), a Noguchi Shitagau Research Grant from the Noguchi Institute, and a Grant-in-Aid for JSPS Fellows (grant number 25KJ2110).
END